| Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY … B Zheng, ACA Green, J Tazare, HJ Curtis, L Fisher, L Nab, A Schultze, ... bmj 379, 2022 | 68* | 2022 |
| Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform L Nab, EPK Parker, CD Andrews, WJ Hulme, L Fisher, J Morley, ... The Lancet public health 8 (5), e364-e377, 2023 | 25 | 2023 |
| Approaches to addressing missing values, measurement error, and confounding in epidemiologic studies M van Smeden, BBLP de Vries, L Nab, RHH Groenwold Journal of Clinical Epidemiology 131, 89-100, 2021 | 20 | 2021 |
| Measurement error in continuous endpoints in randomised trials: problems and solutions L Nab, RHH Groenwold, PMJ Welsing, M van Smeden Statistics in medicine 38 (27), 5182-5196, 2019 | 17 | 2019 |
| Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective … ACA Green, HJ Curtis, R Higgins, L Nab, V Mahalingasivam, RM Smith, ... BMJ medicine 2 (1), 2023 | 16 | 2023 |
| Mecor: An R package for measurement error correction in linear regression models with a continuous outcome L Nab, M van Smeden, RH Keogh, RHH Groenwold Computer methods and programs in biomedicine 208, 106238, 2021 | 13 | 2021 |
| Comparative effectiveness of Paxlovid versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients: observational cohort study using … B Zheng, J Tazare, L Nab, A Mehrkar, B MacKenna, B Goldacre, ... medRxiv, 2023.01. 20.23284849, 2023 | 9 | 2023 |
| Changes in COVID-19-related mortality across key demographic and clinical subgroups: an observational cohort study using the OpenSAFELY platform on 18 million adults in England OpenSAFELY Collaborative, L Nab, EPK Parker, CD Andrews, WJ Hulme, ... medRxiv, 2022.07. 30.22278161, 2022 | 9 | 2022 |
| Factors associated with COVID-19 vaccine uptake in people with kidney disease: an OpenSAFELY cohort study EPK Parker, J Tazare, WJ Hulme, C Bates, EJ Carr, J Cockburn, HJ Curtis, ... BMJ open 13 (1), e066164, 2023 | 6 | 2023 |
| Lupus anticoagulant associates with thrombosis in patients with COVID‐19 admitted to intensive care units: A retrospective cohort study T Noordermeer, REG Schutgens, C Visser, E Rademaker, MPM de Maat, ... Research and practice in thrombosis and haemostasis 6 (6), e12809, 2022 | 6 | 2022 |
| ReprohackNL 2019: How libraries can promote research reproducibility through community engagement K Hettne, R Proppert, L Nab, LP Rojas-Saunero, D Gawehns IASSIST Quarterly 44 (1-2), 1-10, 2020 | 6 | 2020 |
| Quantitative bias analysis for a misclassified confounder: a comparison between marginal structural models and conditional models for point treatments L Nab, RHH Groenwold, M van Smeden, RH Keogh Epidemiology 31 (6), 796-805, 2020 | 5 | 2020 |
| Effectiveness of BNT162b2 booster doses in England: an observational study in OpenSAFELY-TPP WJ Hulme, EJ Williamson, E Horne, A Green, L Nab, R Keogh, ... medRxiv, 2022.06. 06.22276026, 2022 | 4 | 2022 |
| Sampling Strategies for Internal Validation Samples for Exposure Measurement–Error Correction: A Study of Visceral Adipose Tissue Measures Replaced by Waist Circumference Measures L Nab, M van Smeden, R de Mutsert, FR Rosendaal, RHH Groenwold American Journal of Epidemiology 190 (9), 1935-1947, 2021 | 4 | 2021 |
| Estimating incidence of venous thromboembolism in COVID‐19: Methodological considerations L Nab, RHH Groenwold, FA Klok, S Bhoelan, MJHA Kruip, ... Research and practice in thrombosis and haemostasis 6 (6), e12776, 2022 | 3 | 2022 |
| Sensitivity analysis for random measurement error using regression calibration and simulation-extrapolation L Nab, RHH Groenwold Global Epidemiology 3, 100067, 2021 | 3 | 2021 |
| Clinical and health inequality risk factors for non-COVID-related sepsis during the global COVID-19 pandemic: a national case-control and cohort study X Zhong, D Ashiru-Oredope, A Pate, GP Martin, A Sharma, P Dark, ... EClinicalMedicine 66, 2023 | 2 | 2023 |
| Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during … B Zheng, J Tazare, L Nab, ACA Green, HJ Curtis, V Mahalingasivam, ... The Lancet Regional Health–Europe 34, 2023 | 2 | 2023 |
| Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the … B Zheng, J Campbell, EJ Carr, J Tazare, L Nab, V Mahalingasivam, ... Clinical Kidney Journal 16 (11), 2048-2058, 2023 | 2 | 2023 |
| Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron BA. 1 and BA. 2 sublineages: emulated target trials using the OpenSAFELY platform OpenSAFELY Collaborative, J Tazare, L Nab, B Zheng, WJ Hulme, ... medRxiv, 2023.05. 12.23289914, 2023 | 2 | 2023 |
Rolf Groenwoldprofessor of Clinical Epidemiology, LUMC, Leiden UniversityEmail confirmado em lumc.nl
